Navigation Links
Stereotaxis Releases V-Sono™ Intracardiac Echocardiography Module for the Vdrive™ Remote Navigation System
Date:5/8/2012

ST. LOUIS, May 8, 2012 /PRNewswire/ -- Stereotaxis, Inc. (NASDAQ:   STXS) today announced that the Company has released to the European market the V-Sono™ intracardiac echocardiography manipulator module for the Vdrive™ Remote Navigation System.

Designed to manipulate accessory devices such as variable loop catheters, steerable sheaths, and ultrasound catheters, the Vdrive™ platform combines magnetic navigation with the Odyssey™ information management system to bring precise control during catheter-based EP procedures.

The Company also announced the first human case using the V-Sono™ module has been performed by Dr. Georg Nolker of Herz und Diabeteszentrum Klinik fur Kardiologie in Bad Oeynhausen, Germany on April 30, 2012.  A patient was treated for a complex left persistent atrial fibrillation and Dr. Nolker performed a fully remote intervention, using the Vdrive Duo™ platform (the V-Loop™ module for the circular mapping catheter and the V-Sono™ module for the ICE catheter) in concert with the Niobe® ES Magnetic Navigation System.

Dr. Nolker said, "Intracardiac Echo has been long established to provide patient safety and cardiac visualization without radiation. This new robotic control makes intracardiac echo more stable, precise, and easier to use in a way that has not been previously available."      

About Stereotaxis           

Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. With over 100 patents for use in a hospital's interventional surgical suite, Stereotaxis helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced collaboration of life-saving information. Stereotaxis' core technologies are the Niobe® ES Remote Magnetic Navigation system, the Odyssey™ portfolio of lab optimization, networking and patient information management systems and the Vdrive™ Robotic Mechanical Navigation system and consumables.

The core components of Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere; the V-Loop™ circular mapping catheter manipulator is currently under regulatory review by the U.S. Food and Drug Administration. For more information, please visit www.stereotaxis.com and www.odysseyexperience.com.  

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, our continued access to capital and financial resources, including our ability to extend our current loan facility and to obtain additional capital through other financing arrangements, in each case on a timely basis and on terms that are acceptable, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, the outcome of various shareholder litigation recently filed against us, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.


'/>"/>
SOURCE Stereotaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stereotaxis Market Leadership Reinforced in Core Curriculum and Symposium Presentations at Heart Rhythm 2008
2. Stereotaxis Receives Commitment to Increase and Extend Its Credit Facility With Silicon Valley Bank
3. Stereotaxis Announces Public Offering of Common Stock
4. Stereotaxis Announces Pricing of $26 Million Common Stock Offering
5. Stereotaxis Announces Underwriters Exercise of Over-Allotment Option
6. Stereotaxis Receives Notice of European Approval of an Additional Magnetic Irrigated Catheter
7. Stereotaxis System Procedure Featured on NBCs The TODAY Show
8. Stereotaxis is Notified of the FDA Approval of an Additional Magnetic Irrigated Catheter
9. Stereotaxis Installs First System in Taiwan
10. Stereotaxis Updates Progress on Major Clinical Initiative Related to Electrophysiology (EP) Treatment of Ventricular Tachycardia
11. Stereotaxis Announces Vdrive(TM), a New Technology for Remote Navigation of Diagnostic Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Quebec , Dec. 8, 2016  Valeant ... and TSX: VRX) ("Valeant") today announced positive results ... clinical study to assess the safety and efficacy ... the treatment of plaque psoriasis. ... subjects with moderate to severe psoriasis, IDP-118 showed ...
(Date:12/8/2016)... Dec. 8, 2016 True Health Diagnostics ... leading-edge laboratory services and management expertise to hospital ... , allowing more doctors and patients to benefit ... solutions. Logo - http://photos.prnewswire.com/prnh/20161208/447162LOGO ... systems, under pressure to contain costs, have struggled ...
(Date:12/8/2016)... -- Information products and services provider Elsevier ... , the world,s largest abstract and citation database of peer-reviewed literature, ... from over 5,000 publishers. The new set of metrics will improve ... when to adjust a journal,s editorial strategy. ... , , CiteScore ...
Breaking Medicine Technology:
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... Presence Suite 10.2 version gives development continuity to its innovative Unified Instance ... channels management capacity. In addition, this new version optimizes the unattended auto-dialing ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... as possible. With this in mind, SIGVARIS has created a new line of ... during bed rest and provide the benefits of graduated compression when transitioning from ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... from offices headquartered in Jefferson County, is announcing the launch of a charity ... , The number of homeless women and children in Birmingham has grown steadily ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... families and business owners in and around central Kansas, is joining the Youth ... youth in the region. , Headquartered in Wichita, Youth Horizons works to empower ...
(Date:12/7/2016)... ... December 07, 2016 , ... Children exposed to ... researcher at the Icahn School of Medicine at Mount Sinai has found. The ... when young children are exposed to secondhand marijuana smoke, measurable amounts of primary ...
Breaking Medicine News(10 mins):